Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement PR Newswire CAMBRIDGE, Mass., Jan. 6...
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS PR Newswire CAMBRIDGE, Mass., Dec...
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass...
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC PR Newswire CAMBRIDGE, Mass...
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival...
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price PR...
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND PR Newswire CAMBRIDGE...
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission PR Newswire CAMBRIDGE...
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients PR Newswire CAMBRIDGE, Mass., Oct...
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides...
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada PR...
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting PR...
NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and...
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule PR Newswire CAMBRIDGE, Mass., Sept. 24, 2024...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지